PRLHR Immune Genes Associated With Tumor Mutation Burden can be Used as Prognostic Markers in Patients With Gliomas

Tumor mutation burden (TMB) is a useful biomarker for predicting the prognosis and efficacy of immune checkpoint inhibitor (ICIs). In this study, we aimed to explore the prognostic value of TMB and TMB-related PRLHR immune genes as prognostic markers in patients with gliomas. We downloaded MAF files...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yi, Xiang, Juan, Peng, Gang, Shen, Chenfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253814/
https://www.ncbi.nlm.nih.gov/pubmed/35800054
http://dx.doi.org/10.3389/fonc.2022.620190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253814/
https://www.ncbi.nlm.nih.gov/pubmed/35800054
http://dx.doi.org/10.3389/fonc.2022.620190

Ejemplares similares